ZRS Labs

ZRS Labs is a pre-clinical stage biotechnology company focused on the biology of Z-DNA and Z-RNA to develop novel therapies for cancer and inflammatory diseases. The company was founded by Dr. Alan Herbert, a pioneer in the field who discovered the Z-alpha domain that specifically binds to Z-DNA. ZRS Labs targets the innate immune system by modulating the activity of ADAR1 and ZBP1, proteins that recognize and respond to Z-form nucleic acids. Their lead programs aim to inhibit ADAR1 to induce immunogenic cell death in tumors, thereby enhancing the efficacy of existing immunotherapies. The company's platform leverages a unique understanding of nucleic acid flip mechanisms to create a new class of precision medicines. By targeting the dark matter of the genome, ZRS Labs seeks to unlock new pathways for treating cold tumors and chronic inflammation.